A/Prof. Karen Sheppard
Honorary
The Sir Peter Maccallum Department of Oncology
45 Scholarly works
6 Projects
HIGHLIGHTS
2021
Journal article
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
DOI: 10.1158/2159-8290.CD-20-15542019
Research Grant
INHIBITION OF PRMT5 AS A CANCER THERAPY
2017
Research Grant
NOVEL APPROACHES FOR OVERCOMING RESISTANCE TO THERAPIES FOR ADVANCED MELANOMA
2015
Journal article
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
DOI: 10.1126/scisignal.aab11112014
Journal article
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
DOI: 10.1158/2159-8290.CD-13-04402013
Journal article
Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours
DOI: 10.1038/srep034942013
Research Grant
Targetting deregulated signalling pathways in high-grade serous ovarian cancer: Defining therapeutic response and mechanisms of resistance
RECENT SCHOLARLY WORKS
2021
Journal article
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
DOI: 10.3390/cancers132051362021
Journal article
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
DOI: 10.1136/jitc-2021-0029952021
Journal article
Is resistance to targeted therapy in cancer inevitable?
DOI: 10.1016/j.ccell.2021.07.0132021
Journal article
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
DOI: 10.3389/fimmu.2021.6617372021
Journal article
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway
DOI: 10.3390/cancers130305242021
Journal article
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
DOI: 10.1158/2326-6066.CIR-20-04012020
Journal article
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
DOI: 10.1038/s41416-020-01158-z2020
Journal article
Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
DOI: 10.1038/s41597-020-00683-z